BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BridgeBio Pharma (Nasdaq: BBIO) announced inducement equity grants approved on November 17, 2025 for 12 new employees totaling 34,199 restricted stock units. Awards vest: one-quarter on November 16, 2026, then one-twelfth of the remainder quarterly thereafter, subject to continued employment.

All awards were granted under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan and were designated as inducement grants under Nasdaq Listing Rule 5635(c)(4). The Plan was originally adopted in November 2019 and amended in February and December 2023.

PALO ALTO, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that on November 17, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 12 new employees in restricted stock units for an aggregate of 34,199 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on November 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.

About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, X, Facebook, Instagram, and YouTube.

BridgeBio Media Contact:
Bubba Murarka, Executive Vice President, Corporate Development
contact@bridgebio.com   
(650)-789-8220

BridgeBio Investor Contact:
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com

FAQ

What did BridgeBio (BBIO) announce on November 19, 2025 about employee equity grants?

BridgeBio announced inducement grants approved November 17, 2025 totalling 34,199 restricted stock units for 12 new employees.

How do BridgeBio's (BBIO) restricted stock units vest and when is the first vesting date?

Each award vests 25% on November 16, 2026, then 1/12 of the remainder quarterly, subject to continued employment.

Under which plan were BridgeBio's (BBIO) inducement awards granted?

The awards were granted under the Amended and Restated 2019 Inducement Equity Plan, amended in February 2023 and December 2023.

Why were BridgeBio's (BBIO) awards described as inducement grants under Nasdaq rule 5635(c)(4)?

They were designated as inducement grants because they were material to newly hired employees entering employment, consistent with Nasdaq Listing Rule 5635(c)(4).

Does BridgeBio (BBIO) disclose how these grants affect share count or dilution?

The announcement specifies 34,199 restricted stock units granted but does not provide total share count or an estimated dilution percentage.